Company Description
Pressure BioSciences, Inc. develops and sells high pressure technology-based instruments, consumables, and services for life sciences and other industries worldwide.
The company’s products/services are based on Ultra Shear Technology platform, which turns hydrophobic oil-based supplements, therapeutics, and other active ingredients to water-soluble, bioavailable, oil-in-water nano emulsion formulations; BaroFold Technology platform, that is used to improve the quality and lower the production costs of protein biotherapeutics; and Pressure Cycling Technology platform which uses alternating cycles of hydrostatic pressure between ambient and ultra-high pressures to control bio-molecular interactions in sample preparation.
It offers Barocycler instrumentations comprising Barocycler 2320EXT, Barocycler HUB440, Barocycler HUB880, and the Shredder SG3; Barocycler consumable products, such as PCT MicroTubes, PCT MicroCaps, and PCT-Micro Pestle; UltraShear Mini, UltraShear K45, and UltraShear Max; and application specific kits, as well as consumable products.
The company also provides pain relief, skincare solutions, personal wellness, athletic recovery, and specialized pet care products.
It serves researchers at academic laboratories, government agencies, biotechnology and pharmaceutical companies, other life science institutions, and food/beverages laboratories.
The company has collaborations with RedShiftBio Inc.; Inova Schar Cancer Center; NYU; Leica Microsystems, GmbH; The Ohio State University; University of Delaware; and Cedars Sinai Medical Center.
The company was formerly known as Boston Biomedica, Inc. and changed its name to Pressure BioSciences, Inc. in September 2014.
Pressure BioSciences, Inc. was incorporated in 1978 and is headquartered in Canton, Massachusetts.
| Country | MA |
| Founded | 1978 |
| IPO Date | Oct 31, 1996 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 16 |
| CEO | Richard T. Schumacher |
Contact Details
Address: 480 Neponset St. Canton, Massachusetts 02021 United States | |
| Phone | 5082301828 |
| Website | pressurebiosciences.com |
Stock Details
| Ticker Symbol | PBIO |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000830656 |
| CUSIP Number | 74112E208 |
| ISIN Number | US74112E2081 |
| Employer ID | 04-2652826 |
| SIC Code | 3826 |
Key Executives
| Name | Position |
|---|---|
| Richard T. Schumacher | Founder, President, Chief Executive Officer, Treasurer, Interim Chief Financial Officer, Clerk and Director |
| Dr. Edmund Y. Ting Ph.D., Sc.D. Ph.D. | Senior Vice President of Engineering |
| Dr. Alexander V. Lazarev Ph.D. | Vice President of Research and Development |
| John B. Hollister | Director of Sales and Marketing |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 17, 2024 | 8-K | Current Report |
| Jul 3, 2024 | 8-K | Current Report |
| Jun 7, 2024 | 10-K | Annual Report |
| May 17, 2024 | NT 10-Q | Notification of inability to timely file Form 10-Q or 10-QSB |
| Apr 22, 2024 | 8-K | Current Report |
| Apr 1, 2024 | NT 10-K | Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 |
| Feb 27, 2024 | DEF 14A | Other definitive proxy statements |
| Jan 25, 2024 | 8-K | Current Report |
| Nov 20, 2023 | 10-Q | Quarterly Report |
| Nov 15, 2023 | NT 10-Q | Notification of inability to timely file Form 10-Q or 10-QSB |